Bendamustine in patients with relapsed or refractory multiple myeloma.

Area of Science:

• Hematology
• Oncology
• Clinical Pharmacology

Background:

• Bendamustine is an established effective therapy for early-line multiple myeloma.
• Limited data exists regarding bendamustine's efficacy in advanced or refractory multiple myeloma cases.

Purpose of the Study:

• To evaluate the effectiveness and safety of bendamustine as salvage therapy in patients with relapsed or refractory multiple myeloma.
• To determine response rates, event-free survival, and overall survival in this patient population.

Main Methods:

• Retrospective analysis of 39 patients with relapsed/refractory multiple myeloma treated with bendamustine salvage therapy.
• Patients received a median of 3 cycles of bendamustine (80-150 mg/m² on days 1+2) after a median of 2 prior therapies.
• Bendamustine was administered as monotherapy in 39% and with steroids in 61% of patients.

Main Results:

• Mild to moderate toxicity was observed.
• Overall response rates included 3% very good partial response (vgPR), 33% partial response (PR), 18% minimal response (MR), and 26% stable disease (SD).
• Median event-free survival was 7 months, and median overall survival was 17 months.

Conclusions:

• Bendamustine demonstrates efficacy and acceptable toxicity in advanced multiple myeloma patients undergoing salvage therapy.
• The findings support further investigation of bendamustine in clinical trials for advanced multiple myeloma.